

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an Anti-Doping Rule Violation by Zeyad El-Karsh asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an Out-of-Competition sample collection session on April 9, 2022, in Saskatoon, SK.
2. Mr. Zeyad El-Karsh (“the Athlete”) was selected for doping control. The sample provided by the Athlete returned an adverse analytical finding for SARM LGD-4033, a non-specified prohibited substance, and Tamoxifen, a specified substance.
3. Following receipt of the CCES’ Notice of Charge, asserting an Anti-Doping Rule Violation (“ADRV”) for the Presence and Use of SARM LGD-4033 and Tamoxifen, the Athlete signed an Early Admission and Acceptance Form, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and carries out the CADP, including providing anti-doping services to national sport organizations and their members.
5. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (“Code”) and its mandatory International Standards. The CCES has implemented the Code and its mandatory International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of Weightlifting Canada Haltérophilie (WCH). According to Part C, Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in the activities of, sport organizations adopting it. The CADP was adopted by WCH on November 27, 2020. Therefore, as a member of WCH and/or as a participant in WCH sport activities, the Athlete is subject to the Rules of the CADP.

Doping Control

7. On April 9, 2022, the CCES conducted an Out-of-Competition doping control session in Saskatoon, SK. Testing was conducted on WCH athletes as part of the CCES’ domestic test distribution plan, all pursuant to the CADP.
8. The Athlete was notified for doping control and, together with the Doping Control Officer (DCO) from the CCES, completed the sample collection process. The Athlete’s sample code number was 4622697.

9. On April 12, 2022, the Athlete's sample was received by the World Anti-Doping Agency (WADA) accredited laboratory, the INRS-Institut Armand-Frappier (INRS), in Laval, QC.

Results Management

10. The adverse analytical finding was received from the INRS on April 29, 2022. The Certificate of Analysis indicated the presence of SARM LGD-4033 and Tamoxifen.
11. SARM LGD-4033 is classified as a non-specified substance and Tamoxifen is classified as a specified substance on the 2022 WADA Prohibited List.
12. On May 10, 2022, the CCES issued a Notification regarding the Athlete's adverse analytical finding.
13. On May 13, 2022, the Athlete accepted a voluntary Provisional Suspension (VPS).
14. On May 25, 2022, the CCES issued a Notice of Charge formally asserting a violation against the Athlete for the Presence and Use of a prohibited substance.
15. In accordance with CADP Rule 10.2.1, given that the athlete's sample contained both non-specified and specified substances, the standard sanction for an anti-doping violation involving the presence of a non-specified substance is a four (4) year period of ineligibility. The CCES proposed the standard four (4) year period of ineligibility in its Notice of Charge of May 25, 2022.

Confirmation of Violation and Sanction

16. In accordance with CADP Rule 10.8.1, which was specifically referenced within the Notice of Charge, the CCES informed the Athlete on May 25, 2022, that should the Athlete exercise their option to sign the Early Admission and Acceptance Form, the Athlete would receive a one (1) year reduction in the four (4) year period of ineligibility asserted by the CCES.
17. On June 11, 2022, the Athlete signed and submitted the Early Admission and Acceptance Form to the CCES. Accordingly, effective June 11, 2022, an ADRV has been confirmed against the Athlete for the Presence and Use of the identified prohibited substances. In accordance with CADP Rules 10.2.1, 7.4.4, 10.13.2.2 and 10.8.1, the sanction for this violation is a three (3) year period of ineligibility which commenced on May 13, 2022, (the date the athlete accepted a Provisional Suspension) and concludes on May 12, 2025. Further, in accordance with CADP Rule 10.10, any competitive results obtained by the Athlete, from date of sample collection, must be disqualified.
18. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 27th day of June 2022.



Jeremy Luke
Executive Director, Sport Integrity
CCES